department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

tulisokibart · pharmadog

pharmadog
drugs
tulisokibart

drug · antibody

patient view →

tulisokibart

Phase 2updated 2mo ago

by $MRK Merck & Co., Inc.🔗 ChEMBL

Phase 2

community read0 votes

Antibody drug with a maximum clinical stage of Phase 3 (across all indications), with 4 investigational indications.

all catalysts(1)

phase 2 completion · 1

phase 2 completion

Merck & Co Inc — tulisokibart (Phase II Trial Completion)

News(0)

no news has mentioned this drug yet

generic

tulisokibart

indication

Systemic Sclerosis (Scleroderma)

phase

phase_2

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

$MRK126.78-2.15%

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 3

tagPulmonology3 co-mentions · 1 sources
drugImmunology1 co-mentions · 1 sources
tagImmunology1 co-mentions · 1 sources

Trials studying tulisokibart

phase2Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)recruitingn=140
phase3A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)recruitingn=1,200
phase3Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)recruitingn=1,380
phase2Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)active not recruitingn=154
phase2A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)recruitingn=182
phase2A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006)completedn=55
phase2A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)recruitingn=315
phase1A Study of MK-7240 in Healthy Participants (MK-7240-009)recruitingn=330

more trials →